Authors
Carlos Torrado, Amanda Brink, Mohamed Alaa Gouda, Lei Kang, Jessica Osburn, Clover J Patterson, Sheena Charles, Anna Poullard, Gabriele E Urschel, Ecaterina Elena Dumbrava, Daniel D Karp, Aung Naing, Sarina A Piha-Paul, Paula R Pohlmann, Jordi Rodon Ahnert, Apostolia Maria Tsimberidou, Timothy A Yap, David S Hong, Funda Meric-Bernstam, Siqing Fu
Publication date
2024/6/1
Source
Journal of Clinical Oncology
Volume
42
Issue
16_suppl
Pages
1635-1635
Publisher
American Society of Clinical Oncology
Description
1635
Background: Recruitment to phase I/II clinical trials have been reported to vary between 30% and 55% across centers, primarily relying on in-person visits. However, with the onset of the COVID-19 pandemic, there has been a noticeable surge in telehealth consultations. Consequently, there is currently a dearth of data available regarding this approach within the context of early phase-clinical trials. Methods: Data on patient’s first visits to the Investigational Cancer Therapeutics (ICT), a dedicated Phase I department at The University of Texas MD Anderson Cancer Center (MDACC), were retrieved from the institution's electronic platform. The ICT department offers phase I-II clinical trials for patients with advanced cancer. We included first visits between January 2020 and December 2023. Initial telehealth visits were conducted via video or telephone, with patients from either Texas or other states in the United …
Scholar articles